about
Triptans for the management of migraine.Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.A review of the use of frovatriptan in the treatment of menstrually related migraine.Migraine in the triptan era: progresses achieved, lessons learned and future developments.Pharmacokinetic evaluation of frovatriptan.Pharmacological synergy: the next frontier on therapeutic advancement for migraine.Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice.Insights into direct nose to brain delivery: current status and future perspective.Microneedle-assisted transdermal delivery of Zolmitriptan: effect of microneedle geometry, in vitro permeation experiments, scaling analyses and numerical simulations.Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues.Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy.Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan.Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines.Microemulsion based intranasal delivery system for treatment of insomnia.Overview of migraine treatment.Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting.Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.Analytical Quality by Design in pharmaceutical quality assurance: Development of a capillary electrophoresis method for the analysis of zolmitriptan and its impurities.
P2860
Q34129854-3177188F-581F-455B-9F94-613385472C9AQ36373560-85558611-7047-4BEC-8253-0D941E31AB40Q36638660-5E6F3F6D-2A24-429F-9347-CEA927480794Q37558323-482EEB0B-2FC1-4775-8198-CEB07CD5086FQ37935031-E5A3285B-F63A-4C57-B1AC-7C61B775C332Q37973436-E0408497-E24E-472D-A98C-EAA0645786FCQ38046616-97BF10B6-8B9F-4FF4-9B78-0BC686FAB594Q38150429-075A0CE6-362B-43BE-AE0B-C07AD1D518A7Q38856513-CBD35949-53F6-413A-80A8-601B30609CEFQ38866983-08949737-823B-4E41-9B26-BD60E667E746Q39333985-0728DE39-0947-4BBD-BD23-FFA9B5DB9BC1Q41619376-53D3EF60-FA37-489E-B230-32DC3D987018Q41831096-0A75EA11-7A2B-4F8C-96D7-F5DE929C4691Q43921835-F8D142C8-23DA-422D-9E61-6CD5965F83A0Q45974688-2FF569B1-0B92-43CF-8AD3-37DECDB3EB17Q46098987-6F6A43DD-D01F-4BFE-BE04-12F237159761Q46731832-90A181DB-9F91-4D4B-8A61-1DD84DC79BF1Q49873285-8E448098-7BAE-4EC9-9265-79FC42A995BDQ50974115-5690358F-6242-44A1-88E9-F5F90F5AF22D
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The triptan formulations: a critical evaluation.
@ast
The triptan formulations: a critical evaluation.
@en
The triptan formulations: a critical evaluation.
@nl
type
label
The triptan formulations: a critical evaluation.
@ast
The triptan formulations: a critical evaluation.
@en
The triptan formulations: a critical evaluation.
@nl
prefLabel
The triptan formulations: a critical evaluation.
@ast
The triptan formulations: a critical evaluation.
@en
The triptan formulations: a critical evaluation.
@nl
P2093
P2860
P1476
The triptan formulations: a critical evaluation.
@en
P2093
Ana L Antoniazzi
Carlos A Bordini
José G Speciali
P2860
P304
P356
10.1590/S0004-282X2003000200032
P577
2003-06-09T00:00:00Z